Advertisement

Diuretika

  • Hartmut Oßwald
  • Bernd Mühlbauer

Zusammenfassung

Von den Diuretika werden hauptsächlich Schleifendiuretika und Thiazide verordnet. Aldosteronantagonisten folgen mit deutlichem Abstand. Schleifendiuretika sind die dominierende Gruppe der Diuretika und machten 2013 mehr als 60% der verordneten Tagesdosen dieser Gruppe aus. Der Verordnungsumfang von Schleifendiuretika und Thiaziden als Monopräparate wiederum geringfügig ab. Der seit 10 Jahren zu beobachtenden Rückgang ihrer Kombinationen mit kaliumsparenden Diuretika hat sich weiter fortgesetzt. Der Einsatz von Spironolacton als Monopräparat nahm weiter zu, während seine Kombination mit Furosemid deutlich abnahm.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003): The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560–2571CrossRefGoogle Scholar
  2. Cosin J, Diez J, TORIC investigators (2002): Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4: 507–513PubMedGoogle Scholar
  3. Düsing R, Piesche L (1990): Second line therapy of congestive heart failure with torasemide. Prog Pharmacol Clin Pharmacol 8: 105–120Google Scholar
  4. Gentilini P, Laffi G, La Villa G, Carloni V, Foschi M, Romanelli RG, Marra F (1993): Torasemide in the treatment of patients with cirrhosis and ascites. Cardiovasc Drugs Ther 7 (Suppl 1): 81–85PubMedGoogle Scholar
  5. Jacob MS, Tang WH (2011): Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. Curr Heart Fail Rep. 8: 7–13PubMedCrossRefGoogle Scholar
  6. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004): Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543–551PubMedCrossRefGoogle Scholar
  7. Lachaine J, Beauchemin C, Ramos E (2011): Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin Pharmacol May 20; 11: 4. doi: 10.1186/1472-6904-11-4Google Scholar
  8. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al (2001): Open label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 111: 513–520PubMedCrossRefGoogle Scholar
  9. Oßwald H, Vallon V, Luippold G, Gleiter CH (2004): Diuretika - Physiologie, Pharmakologie und klinische Anwendungen. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  10. Pitt B, Nicklas J (2009): Loop diuretics in patients with heart failure: time to change to torsemide? J Cardiovasc Pharmacol 53: 435–437PubMedCrossRefGoogle Scholar
  11. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003): Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321Google Scholar
  12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999): The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717PubMedGoogle Scholar
  13. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003): Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289: 2534–2544PubMedGoogle Scholar
  14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2003): Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997Google Scholar
  15. Wargo KA, Banta WM (2009): Acomprehensive review of the loop diuretics: Should furosemide be the first line? Ann Pharmacother 43: 1836–1847PubMedCrossRefGoogle Scholar
  16. Wilcox CS (2002): New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13: 798–805PubMedGoogle Scholar
  17. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group (2011): Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11–21Google Scholar
  18. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL (2006): Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48: 219–224PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Hartmut Oßwald
    • 1
  • Bernd Mühlbauer
    • 2
  1. 1.Department of Medical Genetics and ENT DepartmentUniversity of Antwerp (UIA)Emmendingen
  2. 2.Institut für Klinische PharmakologieBremen

Personalised recommendations